Verrica Pharmaceuticals (NASDAQ:VRCA) CFO John Kirby Acquires 3,536 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CFO John Kirby purchased 3,536 shares of Verrica Pharmaceuticals stock in a transaction on Tuesday, November 25th. The stock was bought at an average price of $4.24 per share, for a total transaction of $14,992.64. Following the completion of the acquisition, the chief financial officer owned 8,962 shares in the company, valued at $37,998.88. The trade was a 65.17% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Verrica Pharmaceuticals Stock Up 8.5%

VRCA opened at $5.12 on Wednesday. The company has a market capitalization of $48.59 million, a PE ratio of -1.50 and a beta of 1.70. The firm has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $5.44. Verrica Pharmaceuticals Inc. has a 52 week low of $3.28 and a 52 week high of $13.60.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Friday, November 14th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $1.27. The firm had revenue of $14.34 million during the quarter, compared to the consensus estimate of $8.34 million. As a group, sell-side analysts expect that Verrica Pharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VRCA. Bridgeway Capital Management LLC bought a new position in Verrica Pharmaceuticals during the third quarter valued at $52,000. Qube Research & Technologies Ltd purchased a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth about $28,000. AQR Capital Management LLC boosted its stake in shares of Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after purchasing an additional 44,275 shares during the period. Invesco Ltd. grew its holdings in Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock valued at $33,000 after purchasing an additional 29,256 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Verrica Pharmaceuticals by 127.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock valued at $44,000 after buying an additional 55,852 shares during the period. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.